Several other analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Arcadia Biosciences in a research report on Monday, August 12th. National Securities boosted their target price on shares of Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th.
RKDA stock opened at $4.35 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.29 and a quick ratio of 5.09. Arcadia Biosciences has a 12 month low of $1.82 and a 12 month high of $10.40. The firm has a 50 day moving average of $5.97 and a two-hundred day moving average of $5.08.
In other news, Director Kevin Comcowich acquired 5,000 shares of Arcadia Biosciences stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $5.88 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now owns 20,000 shares of the company’s stock, valued at $117,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Matthew T. Plavan acquired 8,000 shares of Arcadia Biosciences stock in a transaction dated Wednesday, August 28th. The stock was purchased at an average price of $8.73 per share, with a total value of $69,840.00. The disclosure for this purchase can be found here. Insiders acquired 33,200 shares of company stock valued at $227,886 over the last three months. Insiders own 3.30% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. CVI Holdings LLC acquired a new stake in shares of Arcadia Biosciences in the second quarter worth $414,000. Vanguard Group Inc. lifted its stake in shares of Arcadia Biosciences by 47.1% in the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after buying an additional 37,472 shares during the last quarter. Morgan Stanley lifted its stake in shares of Arcadia Biosciences by 162,800.0% in the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock worth $250,000 after buying an additional 81,400 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Arcadia Biosciences in the second quarter worth $34,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Arcadia Biosciences in the second quarter worth $32,000. Institutional investors and hedge funds own 6.58% of the company’s stock.
About Arcadia Biosciences
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Featured Story: What are catch-up contributions?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.